nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—HTR2A—phrenic nerve—lung cancer	0.018	0.274	CbGeAlD
Cabergoline—CYP3A4—Topotecan—lung cancer	0.0132	0.142	CbGbCtD
Cabergoline—CYP3A4—Gefitinib—lung cancer	0.012	0.13	CbGbCtD
Cabergoline—CYP3A4—Teniposide—lung cancer	0.0117	0.126	CbGbCtD
Cabergoline—HTR7—pulmonary artery—lung cancer	0.0105	0.159	CbGeAlD
Cabergoline—CYP3A4—Vinorelbine—lung cancer	0.00928	0.1	CbGbCtD
Cabergoline—CYP3A4—Crizotinib—lung cancer	0.00738	0.0796	CbGbCtD
Cabergoline—CYP3A4—Erlotinib—lung cancer	0.00712	0.0768	CbGbCtD
Cabergoline—CYP3A4—Paclitaxel—lung cancer	0.00652	0.0703	CbGbCtD
Cabergoline—HTR2A—pulmonary artery—lung cancer	0.00652	0.0994	CbGeAlD
Cabergoline—CYP3A4—Irinotecan—lung cancer	0.00643	0.0694	CbGbCtD
Cabergoline—CYP3A4—Vinblastine—lung cancer	0.00572	0.0617	CbGbCtD
Cabergoline—CYP3A4—Etoposide—lung cancer	0.00515	0.0556	CbGbCtD
Cabergoline—CYP3A4—Docetaxel—lung cancer	0.00471	0.0508	CbGbCtD
Cabergoline—CYP3A4—Doxorubicin—lung cancer	0.00351	0.0379	CbGbCtD
Cabergoline—ADRA1D—epithelium—lung cancer	0.00247	0.0376	CbGeAlD
Cabergoline—ADRB1—bronchus—lung cancer	0.00176	0.0269	CbGeAlD
Cabergoline—HTR7—respiratory system—lung cancer	0.00176	0.0268	CbGeAlD
Cabergoline—DRD2—respiratory system—lung cancer	0.00166	0.0253	CbGeAlD
Cabergoline—ADRB1—cardiac atrium—lung cancer	0.00149	0.0227	CbGeAlD
Cabergoline—HTR7—epithelium—lung cancer	0.00147	0.0224	CbGeAlD
Cabergoline—ADRA1A—epithelium—lung cancer	0.00142	0.0216	CbGeAlD
Cabergoline—ADRA2C—bronchus—lung cancer	0.00133	0.0203	CbGeAlD
Cabergoline—HTR7—trachea—lung cancer	0.0013	0.0198	CbGeAlD
Cabergoline—ADRA2C—trachea—lung cancer	0.00119	0.0182	CbGeAlD
Cabergoline—ADRB1—lung—lung cancer	0.00114	0.0174	CbGeAlD
Cabergoline—ADRA2C—cardiac atrium—lung cancer	0.00112	0.0171	CbGeAlD
Cabergoline—HTR2A—respiratory system—lung cancer	0.0011	0.0167	CbGeAlD
Cabergoline—HTR2B—lung—lung cancer	0.00109	0.0166	CbGeAlD
Cabergoline—ADRA2A—bronchus—lung cancer	0.00106	0.0162	CbGeAlD
Cabergoline—ADRA2A—trachea—lung cancer	0.000953	0.0145	CbGeAlD
Cabergoline—HTR7—lung—lung cancer	0.000933	0.0142	CbGeAlD
Cabergoline—HTR2A—epithelium—lung cancer	0.000916	0.014	CbGeAlD
Cabergoline—ADRA2A—cardiac atrium—lung cancer	0.000895	0.0136	CbGeAlD
Cabergoline—DRD2—lung—lung cancer	0.000883	0.0135	CbGeAlD
Cabergoline—ADRA2C—lung—lung cancer	0.000858	0.0131	CbGeAlD
Cabergoline—HTR2A—trachea—lung cancer	0.00081	0.0124	CbGeAlD
Cabergoline—HTR2B—lymph node—lung cancer	0.000746	0.0114	CbGeAlD
Cabergoline—ADRA2A—lung—lung cancer	0.000685	0.0104	CbGeAlD
Cabergoline—ADRA2C—lymph node—lung cancer	0.000587	0.00895	CbGeAlD
Cabergoline—HTR2A—lung—lung cancer	0.000582	0.00887	CbGeAlD
Cabergoline—ADRA2A—lymph node—lung cancer	0.000468	0.00714	CbGeAlD
Cabergoline—Pruritus—Vinorelbine—lung cancer	0.000457	0.000848	CcSEcCtD
Cabergoline—Discomfort—Etoposide—lung cancer	0.000457	0.000847	CcSEcCtD
Cabergoline—Constipation—Irinotecan—lung cancer	0.000456	0.000845	CcSEcCtD
Cabergoline—Pain—Irinotecan—lung cancer	0.000456	0.000845	CcSEcCtD
Cabergoline—Arthralgia—Paclitaxel—lung cancer	0.000454	0.000841	CcSEcCtD
Cabergoline—Hypotension—Cisplatin—lung cancer	0.000452	0.000839	CcSEcCtD
Cabergoline—Anxiety—Paclitaxel—lung cancer	0.000452	0.000838	CcSEcCtD
Cabergoline—Face oedema—Doxorubicin—lung cancer	0.000452	0.000838	CcSEcCtD
Cabergoline—Decreased appetite—Gemcitabine—lung cancer	0.000452	0.000837	CcSEcCtD
Cabergoline—Nausea—Topotecan—lung cancer	0.000449	0.000832	CcSEcCtD
Cabergoline—Discomfort—Paclitaxel—lung cancer	0.000448	0.000831	CcSEcCtD
Cabergoline—Abdominal discomfort—Methotrexate—lung cancer	0.000448	0.00083	CcSEcCtD
Cabergoline—Fatigue—Gemcitabine—lung cancer	0.000448	0.00083	CcSEcCtD
Cabergoline—Confusional state—Etoposide—lung cancer	0.000447	0.000829	CcSEcCtD
Cabergoline—Pain—Gemcitabine—lung cancer	0.000444	0.000823	CcSEcCtD
Cabergoline—Constipation—Gemcitabine—lung cancer	0.000444	0.000823	CcSEcCtD
Cabergoline—Nausea—Erlotinib—lung cancer	0.000444	0.000823	CcSEcCtD
Cabergoline—Dry mouth—Paclitaxel—lung cancer	0.000444	0.000822	CcSEcCtD
Cabergoline—Diarrhoea—Vinorelbine—lung cancer	0.000442	0.00082	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000441	0.000818	CcSEcCtD
Cabergoline—Feeling abnormal—Irinotecan—lung cancer	0.000439	0.000815	CcSEcCtD
Cabergoline—Confusional state—Paclitaxel—lung cancer	0.000439	0.000813	CcSEcCtD
Cabergoline—Blood creatinine increased—Doxorubicin—lung cancer	0.000439	0.000813	CcSEcCtD
Cabergoline—Back pain—Docetaxel—lung cancer	0.000437	0.00081	CcSEcCtD
Cabergoline—Gastrointestinal pain—Irinotecan—lung cancer	0.000436	0.000808	CcSEcCtD
Cabergoline—Oedema—Paclitaxel—lung cancer	0.000435	0.000806	CcSEcCtD
Cabergoline—Paraesthesia—Cisplatin—lung cancer	0.000435	0.000806	CcSEcCtD
Cabergoline—Muscle spasms—Docetaxel—lung cancer	0.000434	0.000805	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Methotrexate—lung cancer	0.000434	0.000805	CcSEcCtD
Cabergoline—Liver function test abnormal—Doxorubicin—lung cancer	0.000432	0.000801	CcSEcCtD
Cabergoline—Dyspnoea—Cisplatin—lung cancer	0.000432	0.0008	CcSEcCtD
Cabergoline—Hyperhidrosis—Etoposide—lung cancer	0.000429	0.000795	CcSEcCtD
Cabergoline—Feeling abnormal—Gemcitabine—lung cancer	0.000428	0.000793	CcSEcCtD
Cabergoline—Shock—Paclitaxel—lung cancer	0.000428	0.000793	CcSEcCtD
Cabergoline—Dizziness—Vinorelbine—lung cancer	0.000428	0.000793	CcSEcCtD
Cabergoline—Abdominal pain upper—Doxorubicin—lung cancer	0.000428	0.000792	CcSEcCtD
Cabergoline—Orthostatic hypotension—Doxorubicin—lung cancer	0.000428	0.000792	CcSEcCtD
Cabergoline—Anorexia—Etoposide—lung cancer	0.000423	0.000784	CcSEcCtD
Cabergoline—Abdominal pain—Irinotecan—lung cancer	0.000422	0.000781	CcSEcCtD
Cabergoline—Decreased appetite—Cisplatin—lung cancer	0.000421	0.00078	CcSEcCtD
Cabergoline—Hyperhidrosis—Paclitaxel—lung cancer	0.00042	0.000779	CcSEcCtD
Cabergoline—Pneumonia—Methotrexate—lung cancer	0.000419	0.000777	CcSEcCtD
Cabergoline—Depression—Methotrexate—lung cancer	0.000415	0.00077	CcSEcCtD
Cabergoline—Anorexia—Paclitaxel—lung cancer	0.000415	0.000768	CcSEcCtD
Cabergoline—Hypotension—Etoposide—lung cancer	0.000414	0.000768	CcSEcCtD
Cabergoline—Gastritis—Doxorubicin—lung cancer	0.000414	0.000768	CcSEcCtD
Cabergoline—Pain—Cisplatin—lung cancer	0.000414	0.000767	CcSEcCtD
Cabergoline—Vomiting—Vinorelbine—lung cancer	0.000411	0.000762	CcSEcCtD
Cabergoline—Rash—Vinorelbine—lung cancer	0.000408	0.000756	CcSEcCtD
Cabergoline—Dermatitis—Vinorelbine—lung cancer	0.000407	0.000755	CcSEcCtD
Cabergoline—Hypotension—Paclitaxel—lung cancer	0.000406	0.000753	CcSEcCtD
Cabergoline—Headache—Vinorelbine—lung cancer	0.000405	0.000751	CcSEcCtD
Cabergoline—Syncope—Docetaxel—lung cancer	0.000405	0.000751	CcSEcCtD
Cabergoline—Influenza—Doxorubicin—lung cancer	0.000405	0.00075	CcSEcCtD
Cabergoline—Palpitations—Docetaxel—lung cancer	0.000399	0.00074	CcSEcCtD
Cabergoline—Feeling abnormal—Cisplatin—lung cancer	0.000399	0.00074	CcSEcCtD
Cabergoline—Paraesthesia—Etoposide—lung cancer	0.000398	0.000738	CcSEcCtD
Cabergoline—Loss of consciousness—Docetaxel—lung cancer	0.000397	0.000736	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000396	0.000734	CcSEcCtD
Cabergoline—Dyspnoea—Etoposide—lung cancer	0.000395	0.000733	CcSEcCtD
Cabergoline—Somnolence—Etoposide—lung cancer	0.000394	0.000731	CcSEcCtD
Cabergoline—Insomnia—Paclitaxel—lung cancer	0.000393	0.000729	CcSEcCtD
Cabergoline—Epistaxis—Methotrexate—lung cancer	0.000393	0.000728	CcSEcCtD
Cabergoline—Hypersensitivity—Irinotecan—lung cancer	0.000393	0.000728	CcSEcCtD
Cabergoline—Paraesthesia—Paclitaxel—lung cancer	0.000391	0.000724	CcSEcCtD
Cabergoline—Hypertension—Docetaxel—lung cancer	0.00039	0.000723	CcSEcCtD
Cabergoline—Bronchitis—Doxorubicin—lung cancer	0.000389	0.000721	CcSEcCtD
Cabergoline—Dyspnoea—Paclitaxel—lung cancer	0.000388	0.000719	CcSEcCtD
Cabergoline—Somnolence—Paclitaxel—lung cancer	0.000387	0.000717	CcSEcCtD
Cabergoline—Decreased appetite—Etoposide—lung cancer	0.000386	0.000715	CcSEcCtD
Cabergoline—Arthralgia—Docetaxel—lung cancer	0.000385	0.000713	CcSEcCtD
Cabergoline—Nausea—Vinorelbine—lung cancer	0.000384	0.000712	CcSEcCtD
Cabergoline—Dyspepsia—Paclitaxel—lung cancer	0.000383	0.00071	CcSEcCtD
Cabergoline—Asthenia—Irinotecan—lung cancer	0.000383	0.000709	CcSEcCtD
Cabergoline—Fatigue—Etoposide—lung cancer	0.000382	0.000709	CcSEcCtD
Cabergoline—Pain—Etoposide—lung cancer	0.000379	0.000703	CcSEcCtD
Cabergoline—Constipation—Etoposide—lung cancer	0.000379	0.000703	CcSEcCtD
Cabergoline—Decreased appetite—Paclitaxel—lung cancer	0.000378	0.000701	CcSEcCtD
Cabergoline—Dry mouth—Docetaxel—lung cancer	0.000376	0.000697	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000376	0.000697	CcSEcCtD
Cabergoline—Fatigue—Paclitaxel—lung cancer	0.000375	0.000695	CcSEcCtD
Cabergoline—Asthenia—Gemcitabine—lung cancer	0.000373	0.000691	CcSEcCtD
Cabergoline—Pain—Paclitaxel—lung cancer	0.000372	0.000689	CcSEcCtD
Cabergoline—Constipation—Paclitaxel—lung cancer	0.000372	0.000689	CcSEcCtD
Cabergoline—Confusional state—Docetaxel—lung cancer	0.000372	0.000689	CcSEcCtD
Cabergoline—Oedema—Docetaxel—lung cancer	0.000369	0.000683	CcSEcCtD
Cabergoline—Weight increased—Doxorubicin—lung cancer	0.000368	0.000682	CcSEcCtD
Cabergoline—Pruritus—Gemcitabine—lung cancer	0.000368	0.000681	CcSEcCtD
Cabergoline—Weight decreased—Doxorubicin—lung cancer	0.000366	0.000678	CcSEcCtD
Cabergoline—Feeling abnormal—Etoposide—lung cancer	0.000366	0.000678	CcSEcCtD
Cabergoline—Diarrhoea—Irinotecan—lung cancer	0.000365	0.000676	CcSEcCtD
Cabergoline—Pneumonia—Doxorubicin—lung cancer	0.000363	0.000673	CcSEcCtD
Cabergoline—Gastrointestinal pain—Etoposide—lung cancer	0.000363	0.000672	CcSEcCtD
Cabergoline—Shock—Docetaxel—lung cancer	0.000363	0.000672	CcSEcCtD
Cabergoline—Visual impairment—Methotrexate—lung cancer	0.00036	0.000668	CcSEcCtD
Cabergoline—Feeling abnormal—Paclitaxel—lung cancer	0.000358	0.000664	CcSEcCtD
Cabergoline—Hypersensitivity—Cisplatin—lung cancer	0.000357	0.000661	CcSEcCtD
Cabergoline—Gastrointestinal pain—Paclitaxel—lung cancer	0.000356	0.000659	CcSEcCtD
Cabergoline—Diarrhoea—Gemcitabine—lung cancer	0.000355	0.000659	CcSEcCtD
Cabergoline—Dizziness—Irinotecan—lung cancer	0.000353	0.000654	CcSEcCtD
Cabergoline—Anorexia—Docetaxel—lung cancer	0.000351	0.000651	CcSEcCtD
Cabergoline—Abdominal pain—Etoposide—lung cancer	0.000351	0.00065	CcSEcCtD
Cabergoline—Urinary tract infection—Doxorubicin—lung cancer	0.000351	0.00065	CcSEcCtD
Cabergoline—Asthenia—Cisplatin—lung cancer	0.000347	0.000644	CcSEcCtD
Cabergoline—Cardiac disorder—Methotrexate—lung cancer	0.000347	0.000643	CcSEcCtD
Cabergoline—Hypotension—Docetaxel—lung cancer	0.000344	0.000639	CcSEcCtD
Cabergoline—Abdominal pain—Paclitaxel—lung cancer	0.000344	0.000637	CcSEcCtD
Cabergoline—Epistaxis—Doxorubicin—lung cancer	0.00034	0.000631	CcSEcCtD
Cabergoline—Vomiting—Irinotecan—lung cancer	0.000339	0.000628	CcSEcCtD
Cabergoline—Rash—Irinotecan—lung cancer	0.000336	0.000623	CcSEcCtD
Cabergoline—Dermatitis—Irinotecan—lung cancer	0.000336	0.000623	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000336	0.000623	CcSEcCtD
Cabergoline—Headache—Irinotecan—lung cancer	0.000334	0.000619	CcSEcCtD
Cabergoline—Insomnia—Docetaxel—lung cancer	0.000333	0.000618	CcSEcCtD
Cabergoline—Diarrhoea—Cisplatin—lung cancer	0.000331	0.000614	CcSEcCtD
Cabergoline—Paraesthesia—Docetaxel—lung cancer	0.000331	0.000614	CcSEcCtD
Cabergoline—Alopecia—Methotrexate—lung cancer	0.00033	0.000613	CcSEcCtD
Cabergoline—Vomiting—Gemcitabine—lung cancer	0.00033	0.000612	CcSEcCtD
Cabergoline—Dyspnoea—Docetaxel—lung cancer	0.000329	0.000609	CcSEcCtD
Cabergoline—Somnolence—Docetaxel—lung cancer	0.000328	0.000607	CcSEcCtD
Cabergoline—Rash—Gemcitabine—lung cancer	0.000328	0.000607	CcSEcCtD
Cabergoline—Dermatitis—Gemcitabine—lung cancer	0.000327	0.000607	CcSEcCtD
Cabergoline—Hypersensitivity—Etoposide—lung cancer	0.000327	0.000606	CcSEcCtD
Cabergoline—Headache—Gemcitabine—lung cancer	0.000325	0.000603	CcSEcCtD
Cabergoline—Rhinitis—Doxorubicin—lung cancer	0.000325	0.000602	CcSEcCtD
Cabergoline—Dyspepsia—Docetaxel—lung cancer	0.000324	0.000601	CcSEcCtD
Cabergoline—Decreased appetite—Docetaxel—lung cancer	0.00032	0.000594	CcSEcCtD
Cabergoline—Hypersensitivity—Paclitaxel—lung cancer	0.00032	0.000594	CcSEcCtD
Cabergoline—Oedema peripheral—Doxorubicin—lung cancer	0.000319	0.000591	CcSEcCtD
Cabergoline—Asthenia—Etoposide—lung cancer	0.000318	0.00059	CcSEcCtD
Cabergoline—Fatigue—Docetaxel—lung cancer	0.000318	0.000589	CcSEcCtD
Cabergoline—Nausea—Irinotecan—lung cancer	0.000317	0.000587	CcSEcCtD
Cabergoline—Pain—Docetaxel—lung cancer	0.000315	0.000584	CcSEcCtD
Cabergoline—Constipation—Docetaxel—lung cancer	0.000315	0.000584	CcSEcCtD
Cabergoline—Back pain—Methotrexate—lung cancer	0.000315	0.000584	CcSEcCtD
Cabergoline—Pruritus—Etoposide—lung cancer	0.000314	0.000582	CcSEcCtD
Cabergoline—Visual impairment—Doxorubicin—lung cancer	0.000312	0.000578	CcSEcCtD
Cabergoline—Asthenia—Paclitaxel—lung cancer	0.000312	0.000578	CcSEcCtD
Cabergoline—Nausea—Gemcitabine—lung cancer	0.000309	0.000572	CcSEcCtD
Cabergoline—Vomiting—Cisplatin—lung cancer	0.000308	0.000571	CcSEcCtD
Cabergoline—Pruritus—Paclitaxel—lung cancer	0.000308	0.00057	CcSEcCtD
Cabergoline—Rash—Cisplatin—lung cancer	0.000305	0.000566	CcSEcCtD
Cabergoline—Dermatitis—Cisplatin—lung cancer	0.000305	0.000565	CcSEcCtD
Cabergoline—Feeling abnormal—Docetaxel—lung cancer	0.000304	0.000563	CcSEcCtD
Cabergoline—Diarrhoea—Etoposide—lung cancer	0.000303	0.000563	CcSEcCtD
Cabergoline—Ill-defined disorder—Methotrexate—lung cancer	0.000302	0.00056	CcSEcCtD
Cabergoline—Gastrointestinal pain—Docetaxel—lung cancer	0.000301	0.000559	CcSEcCtD
Cabergoline—Cardiac disorder—Doxorubicin—lung cancer	0.000301	0.000557	CcSEcCtD
Cabergoline—Diarrhoea—Paclitaxel—lung cancer	0.000298	0.000552	CcSEcCtD
Cabergoline—Malaise—Methotrexate—lung cancer	0.000294	0.000544	CcSEcCtD
Cabergoline—Dizziness—Etoposide—lung cancer	0.000293	0.000544	CcSEcCtD
Cabergoline—Vertigo—Methotrexate—lung cancer	0.000292	0.000542	CcSEcCtD
Cabergoline—Abdominal pain—Docetaxel—lung cancer	0.000291	0.00054	CcSEcCtD
Cabergoline—Arrhythmia—Doxorubicin—lung cancer	0.000289	0.000536	CcSEcCtD
Cabergoline—Dizziness—Paclitaxel—lung cancer	0.000288	0.000533	CcSEcCtD
Cabergoline—Nausea—Cisplatin—lung cancer	0.000288	0.000533	CcSEcCtD
Cabergoline—Alopecia—Doxorubicin—lung cancer	0.000286	0.00053	CcSEcCtD
Cabergoline—Vomiting—Etoposide—lung cancer	0.000282	0.000523	CcSEcCtD
Cabergoline—Rash—Etoposide—lung cancer	0.00028	0.000518	CcSEcCtD
Cabergoline—Dermatitis—Etoposide—lung cancer	0.000279	0.000518	CcSEcCtD
Cabergoline—Headache—Etoposide—lung cancer	0.000278	0.000515	CcSEcCtD
Cabergoline—Flatulence—Doxorubicin—lung cancer	0.000278	0.000515	CcSEcCtD
Cabergoline—Arthralgia—Methotrexate—lung cancer	0.000277	0.000514	CcSEcCtD
Cabergoline—Tension—Doxorubicin—lung cancer	0.000277	0.000513	CcSEcCtD
Cabergoline—Vomiting—Paclitaxel—lung cancer	0.000277	0.000513	CcSEcCtD
Cabergoline—Rash—Paclitaxel—lung cancer	0.000274	0.000508	CcSEcCtD
Cabergoline—Dermatitis—Paclitaxel—lung cancer	0.000274	0.000508	CcSEcCtD
Cabergoline—Discomfort—Methotrexate—lung cancer	0.000274	0.000508	CcSEcCtD
Cabergoline—Nervousness—Doxorubicin—lung cancer	0.000274	0.000508	CcSEcCtD
Cabergoline—Back pain—Doxorubicin—lung cancer	0.000273	0.000505	CcSEcCtD
Cabergoline—Headache—Paclitaxel—lung cancer	0.000272	0.000505	CcSEcCtD
Cabergoline—Hypersensitivity—Docetaxel—lung cancer	0.000272	0.000503	CcSEcCtD
Cabergoline—Muscle spasms—Doxorubicin—lung cancer	0.000271	0.000502	CcSEcCtD
Cabergoline—Confusional state—Methotrexate—lung cancer	0.000268	0.000497	CcSEcCtD
Cabergoline—Asthenia—Docetaxel—lung cancer	0.000264	0.00049	CcSEcCtD
Cabergoline—Nausea—Etoposide—lung cancer	0.000263	0.000488	CcSEcCtD
Cabergoline—Ill-defined disorder—Doxorubicin—lung cancer	0.000262	0.000485	CcSEcCtD
Cabergoline—Pruritus—Docetaxel—lung cancer	0.000261	0.000483	CcSEcCtD
Cabergoline—Nausea—Paclitaxel—lung cancer	0.000258	0.000479	CcSEcCtD
Cabergoline—Hyperhidrosis—Methotrexate—lung cancer	0.000257	0.000476	CcSEcCtD
Cabergoline—Malaise—Doxorubicin—lung cancer	0.000254	0.000471	CcSEcCtD
Cabergoline—Vertigo—Doxorubicin—lung cancer	0.000253	0.000469	CcSEcCtD
Cabergoline—Anorexia—Methotrexate—lung cancer	0.000253	0.000469	CcSEcCtD
Cabergoline—Syncope—Doxorubicin—lung cancer	0.000253	0.000469	CcSEcCtD
Cabergoline—Diarrhoea—Docetaxel—lung cancer	0.000252	0.000468	CcSEcCtD
Cabergoline—Palpitations—Doxorubicin—lung cancer	0.000249	0.000462	CcSEcCtD
Cabergoline—Hypotension—Methotrexate—lung cancer	0.000248	0.00046	CcSEcCtD
Cabergoline—Loss of consciousness—Doxorubicin—lung cancer	0.000248	0.000459	CcSEcCtD
Cabergoline—Dizziness—Docetaxel—lung cancer	0.000244	0.000452	CcSEcCtD
Cabergoline—Hypertension—Doxorubicin—lung cancer	0.000243	0.000451	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000242	0.000449	CcSEcCtD
Cabergoline—Insomnia—Methotrexate—lung cancer	0.00024	0.000445	CcSEcCtD
Cabergoline—Arthralgia—Doxorubicin—lung cancer	0.00024	0.000445	CcSEcCtD
Cabergoline—Anxiety—Doxorubicin—lung cancer	0.000239	0.000443	CcSEcCtD
Cabergoline—Paraesthesia—Methotrexate—lung cancer	0.000239	0.000442	CcSEcCtD
Cabergoline—Discomfort—Doxorubicin—lung cancer	0.000237	0.00044	CcSEcCtD
Cabergoline—Dyspnoea—Methotrexate—lung cancer	0.000237	0.000439	CcSEcCtD
Cabergoline—Somnolence—Methotrexate—lung cancer	0.000236	0.000438	CcSEcCtD
Cabergoline—Dry mouth—Doxorubicin—lung cancer	0.000235	0.000435	CcSEcCtD
Cabergoline—Vomiting—Docetaxel—lung cancer	0.000234	0.000434	CcSEcCtD
Cabergoline—Dyspepsia—Methotrexate—lung cancer	0.000234	0.000434	CcSEcCtD
Cabergoline—Rash—Docetaxel—lung cancer	0.000232	0.000431	CcSEcCtD
Cabergoline—Dermatitis—Docetaxel—lung cancer	0.000232	0.00043	CcSEcCtD
Cabergoline—Confusional state—Doxorubicin—lung cancer	0.000232	0.00043	CcSEcCtD
Cabergoline—Decreased appetite—Methotrexate—lung cancer	0.000231	0.000428	CcSEcCtD
Cabergoline—Headache—Docetaxel—lung cancer	0.000231	0.000428	CcSEcCtD
Cabergoline—Oedema—Doxorubicin—lung cancer	0.00023	0.000426	CcSEcCtD
Cabergoline—Fatigue—Methotrexate—lung cancer	0.000229	0.000425	CcSEcCtD
Cabergoline—Pain—Methotrexate—lung cancer	0.000227	0.000421	CcSEcCtD
Cabergoline—Shock—Doxorubicin—lung cancer	0.000226	0.00042	CcSEcCtD
Cabergoline—Hyperhidrosis—Doxorubicin—lung cancer	0.000222	0.000412	CcSEcCtD
Cabergoline—Anorexia—Doxorubicin—lung cancer	0.000219	0.000407	CcSEcCtD
Cabergoline—Nausea—Docetaxel—lung cancer	0.000219	0.000406	CcSEcCtD
Cabergoline—Feeling abnormal—Methotrexate—lung cancer	0.000219	0.000406	CcSEcCtD
Cabergoline—Gastrointestinal pain—Methotrexate—lung cancer	0.000217	0.000403	CcSEcCtD
Cabergoline—Hypotension—Doxorubicin—lung cancer	0.000215	0.000398	CcSEcCtD
Cabergoline—Abdominal pain—Methotrexate—lung cancer	0.00021	0.000389	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.00021	0.000389	CcSEcCtD
Cabergoline—Insomnia—Doxorubicin—lung cancer	0.000208	0.000386	CcSEcCtD
Cabergoline—Paraesthesia—Doxorubicin—lung cancer	0.000207	0.000383	CcSEcCtD
Cabergoline—Dyspnoea—Doxorubicin—lung cancer	0.000205	0.00038	CcSEcCtD
Cabergoline—Somnolence—Doxorubicin—lung cancer	0.000205	0.000379	CcSEcCtD
Cabergoline—Dyspepsia—Doxorubicin—lung cancer	0.000203	0.000375	CcSEcCtD
Cabergoline—Decreased appetite—Doxorubicin—lung cancer	0.0002	0.000371	CcSEcCtD
Cabergoline—Fatigue—Doxorubicin—lung cancer	0.000198	0.000368	CcSEcCtD
Cabergoline—Constipation—Doxorubicin—lung cancer	0.000197	0.000365	CcSEcCtD
Cabergoline—Pain—Doxorubicin—lung cancer	0.000197	0.000365	CcSEcCtD
Cabergoline—Hypersensitivity—Methotrexate—lung cancer	0.000196	0.000363	CcSEcCtD
Cabergoline—Asthenia—Methotrexate—lung cancer	0.000191	0.000353	CcSEcCtD
Cabergoline—Feeling abnormal—Doxorubicin—lung cancer	0.00019	0.000351	CcSEcCtD
Cabergoline—Gastrointestinal pain—Doxorubicin—lung cancer	0.000188	0.000349	CcSEcCtD
Cabergoline—Pruritus—Methotrexate—lung cancer	0.000188	0.000348	CcSEcCtD
Cabergoline—Abdominal pain—Doxorubicin—lung cancer	0.000182	0.000337	CcSEcCtD
Cabergoline—Diarrhoea—Methotrexate—lung cancer	0.000182	0.000337	CcSEcCtD
Cabergoline—Dizziness—Methotrexate—lung cancer	0.000176	0.000326	CcSEcCtD
Cabergoline—Hypersensitivity—Doxorubicin—lung cancer	0.00017	0.000314	CcSEcCtD
Cabergoline—Vomiting—Methotrexate—lung cancer	0.000169	0.000313	CcSEcCtD
Cabergoline—Rash—Methotrexate—lung cancer	0.000168	0.000311	CcSEcCtD
Cabergoline—Dermatitis—Methotrexate—lung cancer	0.000167	0.00031	CcSEcCtD
Cabergoline—Headache—Methotrexate—lung cancer	0.000166	0.000309	CcSEcCtD
Cabergoline—Asthenia—Doxorubicin—lung cancer	0.000165	0.000306	CcSEcCtD
Cabergoline—Pruritus—Doxorubicin—lung cancer	0.000163	0.000302	CcSEcCtD
Cabergoline—Nausea—Methotrexate—lung cancer	0.000158	0.000293	CcSEcCtD
Cabergoline—Diarrhoea—Doxorubicin—lung cancer	0.000157	0.000292	CcSEcCtD
Cabergoline—Dizziness—Doxorubicin—lung cancer	0.000152	0.000282	CcSEcCtD
Cabergoline—Vomiting—Doxorubicin—lung cancer	0.000146	0.000271	CcSEcCtD
Cabergoline—Rash—Doxorubicin—lung cancer	0.000145	0.000269	CcSEcCtD
Cabergoline—Dermatitis—Doxorubicin—lung cancer	0.000145	0.000269	CcSEcCtD
Cabergoline—Headache—Doxorubicin—lung cancer	0.000144	0.000267	CcSEcCtD
Cabergoline—Nausea—Doxorubicin—lung cancer	0.000137	0.000253	CcSEcCtD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—lung cancer	1.01e-05	3.34e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—lung cancer	1.01e-05	3.34e-05	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—lung cancer	1.01e-05	3.33e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—SRC—lung cancer	1.01e-05	3.33e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—STAT3—lung cancer	1.01e-05	3.33e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—PIK3CA—lung cancer	1.01e-05	3.33e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NRAS—lung cancer	1e-05	3.32e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—lung cancer	1e-05	3.32e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EP300—lung cancer	1e-05	3.32e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—SRC—lung cancer	1e-05	3.32e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—ERBB2—lung cancer	1e-05	3.31e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—lung cancer	1e-05	3.31e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CASP3—lung cancer	9.99e-06	3.3e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL2—lung cancer	9.97e-06	3.3e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—lung cancer	9.94e-06	3.29e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—lung cancer	9.93e-06	3.29e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—lung cancer	9.92e-06	3.28e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NRAS—lung cancer	9.91e-06	3.28e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—PIK3CA—lung cancer	9.9e-06	3.27e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCND1—lung cancer	9.88e-06	3.27e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	9.88e-06	3.27e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MTOR—lung cancer	9.88e-06	3.27e-05	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	9.87e-06	3.27e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EP300—lung cancer	9.86e-06	3.26e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—JUN—lung cancer	9.86e-06	3.26e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—lung cancer	9.81e-06	3.25e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CASP3—lung cancer	9.78e-06	3.24e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL2—lung cancer	9.76e-06	3.23e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—lung cancer	9.76e-06	3.23e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—SRC—lung cancer	9.75e-06	3.22e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—EP300—lung cancer	9.74e-06	3.22e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—lung cancer	9.73e-06	3.22e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCND1—lung cancer	9.72e-06	3.22e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—lung cancer	9.72e-06	3.21e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—lung cancer	9.71e-06	3.21e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK3—lung cancer	9.7e-06	3.21e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—JUN—lung cancer	9.7e-06	3.21e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KRAS—lung cancer	9.7e-06	3.21e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NRAS—lung cancer	9.69e-06	3.21e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—lung cancer	9.66e-06	3.2e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NRAS—lung cancer	9.64e-06	3.19e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTP1—lung cancer	9.63e-06	3.18e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK3—lung cancer	9.61e-06	3.18e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—SRC—lung cancer	9.59e-06	3.17e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—lung cancer	9.59e-06	3.17e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—lung cancer	9.58e-06	3.17e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KRAS—lung cancer	9.57e-06	3.17e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KRAS—lung cancer	9.57e-06	3.17e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—HRAS—lung cancer	9.57e-06	3.16e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CDKN1A—lung cancer	9.56e-06	3.16e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PTEN—lung cancer	9.54e-06	3.15e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCND1—lung cancer	9.52e-06	3.15e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—HRAS—lung cancer	9.5e-06	3.14e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—JUN—lung cancer	9.5e-06	3.14e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL8—lung cancer	9.49e-06	3.14e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—lung cancer	9.49e-06	3.14e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK3—lung cancer	9.49e-06	3.14e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—PIK3CA—lung cancer	9.45e-06	3.13e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—lung cancer	9.44e-06	3.12e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MYC—lung cancer	9.44e-06	3.12e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—HRAS—lung cancer	9.43e-06	3.12e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CDKN1A—lung cancer	9.4e-06	3.11e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—lung cancer	9.4e-06	3.11e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PTEN—lung cancer	9.38e-06	3.1e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NRAS—lung cancer	9.38e-06	3.1e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CAT—lung cancer	9.37e-06	3.1e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MYC—lung cancer	9.35e-06	3.09e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—lung cancer	9.34e-06	3.09e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—HRAS—lung cancer	9.31e-06	3.08e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—lung cancer	9.3e-06	3.08e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK3—lung cancer	9.28e-06	3.07e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—lung cancer	9.25e-06	3.06e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—lung cancer	9.24e-06	3.06e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK3—lung cancer	9.23e-06	3.05e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MYC—lung cancer	9.23e-06	3.05e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—EGFR—lung cancer	9.23e-06	3.05e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NRAS—lung cancer	9.23e-06	3.05e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	9.21e-06	3.05e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PTEN—lung cancer	9.19e-06	3.04e-05	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	9.17e-06	3.03e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—HRAS—lung cancer	9.16e-06	3.03e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—lung cancer	9.16e-06	3.03e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—lung cancer	9.15e-06	3.03e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—EGFR—lung cancer	9.15e-06	3.03e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—lung cancer	9.14e-06	3.02e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ABCB1—lung cancer	9.11e-06	3.01e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—lung cancer	9.1e-06	3.01e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EP300—lung cancer	9.09e-06	3.01e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CASP3—lung cancer	9.09e-06	3.01e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL2—lung cancer	9.07e-06	3e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—EGFR—lung cancer	9.03e-06	2.99e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—lung cancer	9.03e-06	2.99e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MYC—lung cancer	9.03e-06	2.99e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK3—lung cancer	8.98e-06	2.97e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MYC—lung cancer	8.98e-06	2.97e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—lung cancer	8.96e-06	2.97e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—TYMS—lung cancer	8.95e-06	2.96e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EP300—lung cancer	8.95e-06	2.96e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—PIK3CA—lung cancer	8.91e-06	2.95e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—lung cancer	8.91e-06	2.95e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PIK3CA—lung cancer	8.87e-06	2.93e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTM1—lung cancer	8.85e-06	2.93e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCND1—lung cancer	8.84e-06	2.93e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SRC—lung cancer	8.84e-06	2.93e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK3—lung cancer	8.84e-06	2.92e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—EGFR—lung cancer	8.83e-06	2.92e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—JUN—lung cancer	8.83e-06	2.92e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	8.79e-06	2.91e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—PIK3CA—lung cancer	8.79e-06	2.91e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EGFR—lung cancer	8.78e-06	2.91e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—lung cancer	8.76e-06	2.9e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EP300—lung cancer	8.76e-06	2.9e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—HRAS—lung cancer	8.74e-06	2.89e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MYC—lung cancer	8.73e-06	2.89e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KRAS—lung cancer	8.72e-06	2.88e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SRC—lung cancer	8.7e-06	2.88e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KRAS—lung cancer	8.64e-06	2.86e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—lung cancer	8.62e-06	2.85e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—lung cancer	8.61e-06	2.85e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MYC—lung cancer	8.6e-06	2.84e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—lung cancer	8.59e-06	2.84e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	8.56e-06	2.83e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EGFR—lung cancer	8.54e-06	2.83e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PTEN—lung cancer	8.54e-06	2.82e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KRAS—lung cancer	8.53e-06	2.82e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—lung cancer	8.53e-06	2.82e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SRC—lung cancer	8.52e-06	2.82e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NRAS—lung cancer	8.51e-06	2.81e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—lung cancer	8.51e-06	2.81e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—lung cancer	8.51e-06	2.81e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—lung cancer	8.48e-06	2.8e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—lung cancer	8.45e-06	2.79e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EGFR—lung cancer	8.41e-06	2.78e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—lung cancer	8.39e-06	2.78e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—lung cancer	8.39e-06	2.78e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CYP1A1—lung cancer	8.39e-06	2.77e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NRAS—lung cancer	8.37e-06	2.77e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—lung cancer	8.37e-06	2.77e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KRAS—lung cancer	8.34e-06	2.76e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—lung cancer	8.33e-06	2.76e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ERCC2—lung cancer	8.32e-06	2.75e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—lung cancer	8.3e-06	2.75e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KRAS—lung cancer	8.3e-06	2.75e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—HRAS—lung cancer	8.24e-06	2.73e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—lung cancer	8.22e-06	2.72e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—lung cancer	8.22e-06	2.72e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NRAS—lung cancer	8.2e-06	2.71e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK3—lung cancer	8.15e-06	2.7e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EP300—lung cancer	8.14e-06	2.69e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—HRAS—lung cancer	8.13e-06	2.69e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—HRAS—lung cancer	8.13e-06	2.69e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—lung cancer	8.09e-06	2.68e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KRAS—lung cancer	8.07e-06	2.67e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK3—lung cancer	8.02e-06	2.65e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—PIK3CA—lung cancer	8.01e-06	2.65e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KRAS—lung cancer	7.94e-06	2.63e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	7.94e-06	2.63e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MYC—lung cancer	7.92e-06	2.62e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SRC—lung cancer	7.92e-06	2.62e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—lung cancer	7.89e-06	2.61e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK3—lung cancer	7.85e-06	2.6e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—PIK3CA—lung cancer	7.84e-06	2.59e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MYC—lung cancer	7.8e-06	2.58e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—lung cancer	7.79e-06	2.58e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—lung cancer	7.79e-06	2.58e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EGFR—lung cancer	7.75e-06	2.56e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—lung cancer	7.75e-06	2.56e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—lung cancer	7.72e-06	2.55e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—lung cancer	7.71e-06	2.55e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—lung cancer	7.68e-06	2.54e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PIK3CA—lung cancer	7.66e-06	2.53e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MYC—lung cancer	7.64e-06	2.53e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—lung cancer	7.63e-06	2.53e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EGFR—lung cancer	7.63e-06	2.52e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PIK3CA—lung cancer	7.62e-06	2.52e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NRAS—lung cancer	7.62e-06	2.52e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—lung cancer	7.58e-06	2.51e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EGFR—lung cancer	7.47e-06	2.47e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	7.41e-06	2.45e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—lung cancer	7.41e-06	2.45e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—HRAS—lung cancer	7.41e-06	2.45e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—lung cancer	7.37e-06	2.44e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—HRAS—lung cancer	7.34e-06	2.43e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KRAS—lung cancer	7.32e-06	2.42e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	7.3e-06	2.41e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK3—lung cancer	7.29e-06	2.41e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—lung cancer	7.28e-06	2.41e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—HRAS—lung cancer	7.25e-06	2.4e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—lung cancer	7.24e-06	2.4e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KRAS—lung cancer	7.21e-06	2.38e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PIK3CA—lung cancer	7.2e-06	2.38e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOA1—lung cancer	7.2e-06	2.38e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—lung cancer	7.18e-06	2.38e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—lung cancer	7.18e-06	2.38e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—lung cancer	7.17e-06	2.37e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MYC—lung cancer	7.09e-06	2.35e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—lung cancer	7.09e-06	2.35e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—HRAS—lung cancer	7.09e-06	2.35e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—lung cancer	7.06e-06	2.34e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KRAS—lung cancer	7.05e-06	2.33e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—HRAS—lung cancer	7.05e-06	2.33e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—lung cancer	7.03e-06	2.33e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—lung cancer	6.94e-06	2.3e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EGFR—lung cancer	6.94e-06	2.3e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—HRAS—lung cancer	6.86e-06	2.27e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—lung cancer	6.78e-06	2.24e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—HRAS—lung cancer	6.75e-06	2.23e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—lung cancer	6.75e-06	2.23e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PIK3CA—lung cancer	6.73e-06	2.23e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3CA—lung cancer	6.62e-06	2.19e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CG—lung cancer	6.57e-06	2.17e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—lung cancer	6.57e-06	2.17e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KRAS—lung cancer	6.55e-06	2.17e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—lung cancer	6.54e-06	2.17e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—lung cancer	6.51e-06	2.15e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—lung cancer	6.48e-06	2.15e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	6.48e-06	2.14e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—lung cancer	6.46e-06	2.14e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—lung cancer	6.4e-06	2.12e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—lung cancer	6.4e-06	2.12e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—lung cancer	6.27e-06	2.07e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—lung cancer	6.26e-06	2.07e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—POMC—lung cancer	6.25e-06	2.07e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—lung cancer	6.23e-06	2.06e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—HRAS—lung cancer	6.22e-06	2.06e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—HRAS—lung cancer	6.12e-06	2.03e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CREBBP—lung cancer	6.09e-06	2.01e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—lung cancer	6.06e-06	2e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	6.02e-06	1.99e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—HRAS—lung cancer	6e-06	1.98e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—lung cancer	5.96e-06	1.97e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—lung cancer	5.96e-06	1.97e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—lung cancer	5.88e-06	1.95e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—lung cancer	5.86e-06	1.94e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—lung cancer	5.83e-06	1.93e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CD—lung cancer	5.77e-06	1.91e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—lung cancer	5.74e-06	1.9e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ALB—lung cancer	5.7e-06	1.89e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—HRAS—lung cancer	5.57e-06	1.84e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—lung cancer	5.5e-06	1.82e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—lung cancer	5.41e-06	1.79e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—lung cancer	5.33e-06	1.76e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—lung cancer	5.29e-06	1.75e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CB—lung cancer	5.03e-06	1.67e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—lung cancer	4.99e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—lung cancer	4.92e-06	1.63e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTEN—lung cancer	4.35e-06	1.44e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—EP300—lung cancer	4.15e-06	1.37e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CA—lung cancer	3.07e-06	1.02e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—lung cancer	2.51e-06	8.29e-06	CbGpPWpGaD
